Logo

CRDF

Cardiff Oncology, Inc.

CRDF

Cardiff Oncology, Inc. • NASDAQ
$2.28 ▼ -2.56% (-0.06)
Market Cap $153.50 M
52w High $5.64
52w Low $1.90
Dividend Yield 0%
P/E -2.89
Volume 247.48K
Outstanding Shares 67.32M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $120K ▼ $12.094M ▲ $-11.258M ▲ -9.382K% ▲ $-0.17 ▲ $-10.764M ▲
Q2-2025 $121K ▲ $3.318M ▼ $-13.943M ▼ -11.523K% ▲ $-0.21 ▼ $-14.683M ▼
Q1-2025 $109K ▼ $14.491M ▲ $-13.434M ▼ -12.325K% ▼ $-0.2 ▲ $-14.154M ▼
Q4-2024 $151K ▼ $12.723M ▲ $-11.787M ▲ -7.806K% ▼ $-0.25 $-12.476M ▲
Q3-2024 $165K $3.126M $-11.855M -7.185K% $-0.25 $-12.5M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $60.591M ▼ $63.78M ▼ $14.99M ▼ $48.79M ▼
Q2-2025 $70.957M ▼ $75.739M ▼ $17.133M ▲ $58.606M ▼
Q1-2025 $79.887M ▼ $84.807M ▼ $13.931M ▼ $70.876M ▼
Q4-2024 $91.746M ▲ $97.19M ▲ $14.241M ▲ $82.949M ▲
Q3-2024 $57.667M $62.896M $13.504M $49.392M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.258M ▲ $-10.834M ▼ $10.16M ▲ $25K ▲ $-649K ▲ $-10.852M ▼
Q2-2025 $-13.943M ▼ $-8.328M ▲ $-4.983M ▲ $0 ▼ $-13.311M ▲ $-8.354M ▲
Q1-2025 $-13.434M ▼ $-12.794M ▼ $-14.584M ▼ $3K ▼ $-27.375M ▼ $-12.794M ▼
Q4-2024 $-11.787M ▲ $-10.267M ▲ $4.511M ▲ $44.188M ▲ $38.432M ▲ $-10.267M ▲
Q3-2024 $-11.855M $-10.456M $-9.434M $7.427M $-12.463M $-10.456M

Revenue by Products

Product Q2-2019Q3-2019Q4-2019
Royalty
Royalty
 $0 ▲$0 ▲$0 ▲
Service
Service
 $0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Cardiff Oncology is still a pure R&D story with essentially no product revenue yet. The income statement is driven entirely by research and overhead costs, which result in recurring annual losses. These losses have been fairly steady over the last several years rather than sharply worsening, suggesting disciplined spending but also a continued lack of commercial income. Overall, this looks like a typical clinical‑stage biotech profile: costs to advance the pipeline with no offsetting sales so far.

Balance Sheet

Balance Sheet The company has a small but clean balance sheet. Assets are modest and heavily concentrated in cash and equivalents, with no meaningful debt. Equity remains positive, which is a plus, but the overall resource base is limited. The key takeaway is financial simplicity and an absence of leverage, balanced against the reality that the company will likely need fresh capital over time if trials continue and there is still no revenue.

Cash Flow

Cash Flow Cash flow is consistently negative, driven by operating activities such as clinical trials, staff, and overhead. Capital spending is minimal, so almost all cash use reflects the cost of running the business and advancing onvansertib. The cash burn appears steady rather than explosive, but it still gradually erodes the cash balance. This pattern suggests ongoing dependence on external funding sources—equity raises, partnerships, or other forms of financing—to sustain operations and complete pivotal trials.

Competitive Edge

Competitive Edge Cardiff Oncology is highly focused, with its fortunes tied mainly to a single lead drug, onvansertib. Its edge comes from being a targeted, third‑generation PLK1 inhibitor with promising early results in tough‑to‑treat cancers, especially certain colorectal tumors with KRAS mutations. The company has carved out a niche in an area of high unmet medical need and has validated interest from a large pharma partner. However, oncology is a crowded and rapidly evolving field, and reliance on one main asset, still in clinical development, creates significant competitive and concentration risk.

Innovation and R&D

Innovation and R&D Innovation is the core of Cardiff’s story. Onvansertib is designed as an oral, highly selective cancer drug aimed at a biologically important target, with encouraging safety and activity signals so far. The company is exploring it in combinations with standard treatments and extending it into multiple cancer types, supported by patent protection stretching well into the future. R&D is therefore both the main strength and main risk: success could open several valuable indications, while any clinical or regulatory setbacks would heavily impact the company given its narrow pipeline focus.

Summary

Cardiff Oncology is a classic clinical‑stage biotech: no product revenue yet, recurring but controlled losses, and a balance sheet dominated by cash with no debt. The investment thesis revolves almost entirely around the success of onvansertib, a differentiated and potentially first‑in‑class cancer therapy with encouraging early data and long patent life. The upside case depends on successful trials, regulatory progress, and possibly more partnerships, while the downside centers on clinical risk, ongoing cash burn, and the need for future financing in the absence of commercial sales.

NEWS

November 24, 2025 · 7:00 AM UTC

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Read more

November 6, 2025 · 4:05 PM UTC

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Read more

November 4, 2025 · 4:01 PM UTC

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Read more

October 2, 2025 · 4:05 PM UTC

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Read more